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1607-551X/Copyright ª 2014, KaohsiuAbstract Dipyridamole has been shown to decrease proteinuria and improve renal function
progression especially in early chronic kidney disease (CKD) patients with glomerulonephrop-
athy. A combination therapy of dipyridamole with aspirin could prevent second strokes in
the general population. Whether these effects of dipyridamole are also true in advanced
CKD patients and whether dipyridamole could improve renal outcomes or patient survival is un-
known. We retrospectively analyzed an observational cohort of 3074 participants with CKD
stage 3e5 from southern Taiwan, of whom 871 (28.3%) had received dipyridamole treatment
50 mg/d for 3 months and more than half of the observation period. The mean age was
63.6  13.4 years and the mean estimated glomerular filtration rate (eGFR) was 25.5 mL/
min/1.73 m2. After inverse probability of treatment weighted adjustment by propensity score,
there were no differences between the dipyridamole-treated and untreated groups. Dipyrida-
mole treatment was associated with decreased odds for rapid eGFR decline [odds ratio, 0.755;
95% confidence interval (CI), 0.595e0.958; p Z 0.007] and progression of urine protein-to-
creatinine ratio (odds ratio, 0.655; 95% CI, 0.517e0.832; p Z 0.002). In survival analysis,
the dipyridamole-treated group was also associated with a decreased risk for end-stage renal
disease (hazard ratio, 0.847; 95% CI, 0.733e0.980; pZ 0.011) and all-cause mortality (hazardeclare no conflicts of interest.
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600 C.-C. Hung et al.ratio, 0.765; 95% CI, 0.606e0.971; p Z 0.001) but not for cardiovascular events. Our findings
demonstrate that dipyridamole treatment is significantly associated with better renal out-
comes and patient survival in patients with CKD stage 3e5. Further investigations are war-
ranted to confirm these independent positive effects.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The increasing global prevalence of chronic kidney disease
(CKD), which leads to end-stage renal disease (ESRD) and
premature cardiovascular disease (CVD), has profound
impacts on public health and economic burden [1]. The
current practice guideline proposes effective strategies of
early detection of high-risk groups and provision of
comprehensive management in order to prevent and slow
down the progression of CKD [1,2]. Current approaches
focus on slowing disease progression, reducing proteinuria,
and preventing related complications through interventions
with renineangiotensinealdosterone system blockades,
glycemic and blood pressure control, and dietary protein
restriction [2,3]. However, many patients with CKD still
progress to ESRD and exhibit adverse cardiovascular out-
comes and increased mortality under the current treat-
ments, especially in the population with lower estimated
glomerular filtration rate (eGFR) and higher albuminuria
[4,5].
Dipyridamole, either through monotherapy or in combi-
nation with other antiplatelet agents or immunosuppres-
sants, has been widely used in diabetic nephropathy and
various primary glomerulopathies for its therapeutic effects
on proteinuria and variable effect on renal progression.
These positive reports have been found for patients with
diabetic kidney disease [6], IgA nephropathy [7,8], and
membranoproliferative glomerulonephritis [9]. As in the
consensus reports, proteinuria has been considered a sur-
rogate outcome of CKD. It is still undetermined whether
dipyridamole plays an effective role in renal outcomes in
terms of preventing ESRD in patients with more advanced
CKD.
Furthermore, CVD is the main cause of morbidity and
mortality in patients with CKD [10]. Previous studies have
reported the efficacious effect of dipyridamole in CVD. A
combination therapy of dipyridamole with aspirin has been
shown to prevent second strokes in the general population
[11]. A systemic review demonstrated that dipyridamole
prevents the risk of recurrent vascular events but does not
reduce the risk of vascular death for patients with vascular
disease [12]. Moreover, Jardine et al. [13] also reported
that another antiplatelet agent, aspirin, resulted in better
reduction of the major cardiovascular (CV) events and
mortality in hypertensive patients with CKD than in those
with normal kidney function. However, the beneficial ef-
fects of antiplatelet therapy on CV outcome and mortality
are still unproven for patients with CKD and must be taken
with caution because of the potential hazards of bleedingbased on a systematic review and meta-analysis [14]. Thus,
it is worthwhile to investigate whether dipyridamole ex-
hibits protective benefits on CV events or overall mortality
in patients with CKD.
In the current study, we aimed to investigate whether
dipyridamole treatment has a positive role in improving
proteinuria and the progression of eGFR, the development
of ESRD, CV events, and all-cause mortality in CKD stage
3e5 patients from an observational CKD cohort.
Methods
Participants
Between November 11, 2002 and May 31, 2009, 3749 pa-
tients were enrolled in the Integrated CKD Care Program
from two affiliated hospitals of Kaohsiung Medical Univer-
sity in southern Taiwan as described in detail previously
[15,16]. They were followed up until July 31, 2010. The
following were excluded: 356 patients with CKD stage 1e2;
90 patients lost to follow up in <3 months; and 229 patients
who received medications for <3 months. Thus the final
study population was 3074 CKD stage 3e5 patients.
Demographics and medical information
Baseline information included age, sex, primary renal dis-
eases, blood pressure, body mass index, comorbidities, life
styles, as well as medication histories. Laboratory assess-
ments included eGFR derived from the four-variable Modi-
fication of Diet in Renal Disease Study equation [17], serum
albumin, total cholesterol, triglyceride, C-reactive protein,
total calcium, phosphate, uric acid, hemoglobin, and gly-
cated hemoglobin. Urine protein loss was evaluated by the
urine protein-to-creatinine ratio (UPCR) and dipstick. All
data were collected and averaged from 3 months before to
3 months after enrollment. Dipyridamole treatment was
defined as the daily use of dipyridamole 50 mg/d for >3
months and more than half of the observation period.
Other medication treatment was also defined as their usage
for >3 months and more than half of the observation
period.
Study outcomes
The eGFR decline rate, progression of UPCR and incidence
of renal replacement therapy (RRT), CV events, and
all-cause mortality were assessed. The rapid renal
Dipyridamole and clinical outcomes in CKD 601progression was defined as the eGFR slope <e5 mL/min/
1.73 m2/y [16]. The significant progression of proteinuria
was defined as increased UPCR >100 mg/g/y, which was
the cut-off value of the lowest quartile from our CKD
cohort population in this study. The RRT was defined as
patients reaching kidney failure that demanded the
commencement of hemodialysis, peritoneal dialysis, and
renal transplantation.
CV events were defined as the development of acute
coronary syndrome or acute stroke, hospitalization for
peripheral arterial occlusion disease or congestive heart
failure, and death by the aforementioned causes. Survival
status and cause of death were ascertained by a review
of death certificates using charts or the National Death
Index.Statistical analyses
Continuous variables with normal distribution were pre-
sented as mean  standard deviation and analyzed by
Student t test. Continuous data with skewed distribution
were expressed as median with interquartile range and
were compared using the ManneWhitney U test. Categori-
cal data were analyzed using the Chi-square test. Cox’s
hazard proportional models adjusted for baseline cova-
riates were used to determine the association of dipyr-
idamole with all-cause mortality, CV events, and incidence
of ESRD. Subgroup analyses, based on tests for interaction,
were performed to examine the difference in treatment
effects between selected groups [18]. Models for the all-
cause mortality included patients who reached RRT and
were censored only at death or the end of follow up. Models
for CV events were censored at the development of the
aforementioned events, death, or the end of follow up.
Models for ESRD were censored at the commencement of
RRT, death, or the end of follow up. Binary logistic
regression analysis was used to evaluate the relationship
between dipyridamole and eGFR decline rate as well as
progression of proteinuria.
Propensity score methods were used for reducing the
selection bias on the estimate of the treatment effect in
observational studies [19,20]. Adjustments for the dif-
ferences between dipyridamole treated and untreated
groups were performed by using the inverse probability of
treatment weighted (IPTW) estimator [21]. The pro-
pensity score for dipyridamole treatment of each patient
was obtained by fitting a logistic regression model that
included the predictor variable (i.e., dipyridamole-
treated or untreated patients) as an outcome and all
baseline covariates. After the propensity score was con-
structed, we calculated the propensity score weight as
the inverse of the propensity score. Then, the propensity
score-weighted t test was used to analyze the differences
between dipyridamole-treated and untreated groups.
Furthermore, the propensity score was used as an addi-
tional covariate in the Cox’s hazard proportional models
for outcome analyses.
Statistical analyses were performed using SPSS, version
18.0, (SSPS Inc., Chicago, IL, USA). All statistical tests were
two-tailed, and statistical significance was assumed for
p < 0.05.Results
Clinical characteristics and medical treatment
before and after IPTW adjustment
In the follow up (median, 2.7 years; range, 1.6e4.2
years), a total of 3074 participants of CKD stage 3e5 with
an average age of 63.6  13.4 years and 58.1% males were
included for analysis. Among them, 871 (28.3%) partici-
pants had received dipyridamole treatment for >3 months
and more than half of the follow-up period. Table 1 shows
the clinical characteristics and distribution between
dipyridamole-treated and untreated groups before and
after IPTW adjustment. Before IPTW adjustment, there
were significant differences in sex, and several clinical
and laboratory parameters between the two groups. After
IPTW adjustment, the mean eGFR was 25.6 mL/min/
1.73 m2 and the mean UPCR was 932 mg/g without dif-
ference in both groups and the other variables were also
similar between the two groups except for a higher per-
centage of alcohol drinkers in the dipyridamole-untreated
group.
The prescribed medications are listed in Table 2. Before
IPTW adjustment, the dipyridamole-treated group had
received more medications of angiotensin-converting
enzyme inhibitor (ACEI), a-blockers, phosphate binders,
and erythropoietin stimulating agent, but less oral hypo-
glycemic drugs, nitrates, and low dose-aspirin. After IPTW
adjustment, the rates of medical treatments between the
two groups were similar.
Association between dipyridamole and surrogate
renal outcomes
As shown in Table 3, the dipyridamole-treated group was
associated with less rapid renal progression [odds ratio
(OR), 0.755; 95% confidence interval (CI), 0.595e0.958;
p Z 0.007]. Other medications and factors associated with
less rapid renal progression included the concomitant uses
of ACEI/angiotensin II receptor blockers (ARB), greater age,
higher body mass index (BMI), hemoglobin, and plasma al-
bumin (all p < 0.05). In contrast, proteinuria was associ-
ated with rapid renal progression. Furthermore, the
dipyridamole-treated group was significantly associated
with decreased progression of proteinuria (OR, 0.655; 95%
CI, 0.517e0.832; p Z 0.002) based on the definition with
UPCR change >100 mg/g/y. Other medications and factors
associated with decreased progression of proteinuria
included the concomitant uses of ACEI/ARB and nitrates,
female sex, higher levels of BMI, baseline eGFR, and plasma
albumin (all p < 0.05). In contrast, significant proteinuria
progression was associated with the concomitant uses of
diuretics and phosphate binders, and higher levels of serum
phosphate (all p < 0.05).
Association between dipyridamole and ESRD
There were 295 patients (10.1 events/100 personeyears)
and 646 patients (11.0 events/100 personeyears) who
reached ESRD in the dipyridamole-treated and untreated
Table 1 Baseline demographic and clinical characteristics of participants before and after inverse probability of treatment
weighted adjustment.
Characteristics Number of patients Percent distributiona
DIPY treated
(n Z 871)
DIPY untreated
(n Z 2203)
Before adjustment After adjustment
DIPY treated DIPY untreated DIPY treated DIPY untreated
Male 553 1233 63.5 56.0* 58.9 58.9
Age (y) 62.9  13.6 63.9  13.4 63.6  13.6 63.6  13.5
DM 220 767 25.3 34.8* 28.7 28.6
Hypertension 391 1035 44.9 47 45.8 46.6
CVD 190 609 21.8 27.6* 24.4 24.3
Smoker 200 510 23 23.2 22.1 23.4
Alcohol use 89 276 10.2 12.5 9.3 12.7*
MBP (mmHg) 99.1  13.6 99.9  13.7 99.5  14.0 99.7  13.8
BMI (kg/m2) 24.8  3.8 24.7  4.0 24.7  4.1 24.7  4.0
eGFR (mL/min/1.73 m2)b 25.5  15.0 25.6  14.9 25.6  15.3 25.6  15.1
CKD stage
Stage 3 333 823 38.2 37.4 37.8 37.5
Stage 4 249 684 28.6 31 30.5 29.8
Stage 5 289 696 33.2 31.6 31.2 32.2
UPCR (mg/g) 977  376 891  367 935  371 928  370
Proteinuria
 265 588 30.4 26.7* 27.3 27.3
þ 257 628 29.5 28.5 28.8 28.8
þþ 199 529 22.8 24 23.6 23.6
þþþ w þþþþ 150 458 17.3 20.8* 18.9 18.9
Albumin (g/dL) 3.9  0.5 3.8  0.5* 3.8  0.5 3.8  0.5
Hb (g/dL) 11.2  2.3 11.0  2.3* 11.0  2.4 11.0  2.3
UA (mg/dL) 7.8  1.9 7.9  2.0 7.8  2.0 7.9  2.0
Ca (mg/dL) 9.1  0.7 9.1  0.8 9.0  0.8 9.0  0.8
P (mg/dL) 4.3  1.1 4.4  1.2 4.3  1.2 4.3  1.2
CHOL (mg/dL) 189  55 191  55 196  55 196  54
TG (mg/dL) 159  143 154  141* 158  143 155  141
HbA1c (%) 6.2  1.4 6.6  1.7* 6.5  0.9 6.5  2.4
CRP (mg/L) 0.9  1.0 1.1  0.9* 1.1  0.9 1.1  0.8
*p < 0.05 (DIPY treated vs. DIPY untreated).
BMIZ body mass index; CaZ total serum calcium; CHOLZ total cholesterol; CKDZ chronic kidney disease; CRPZ C-reactive protein;
CVD Z cardiovascular diseases; DIPY Z dipyridamole; DM Z diabetes mellitus; eGFR Z estimated glomerular filtration rate;
Hb Z hemoglobin; HbA1cZ glycated hemoglobin; MBP Z mean blood pressure; P Z serum phosphate; TG Z triglycerides; UA Z uric
acid; UPCR Z urine protein-to-creatinine ratio.
a Continuous variables are expressed as mean  standard deviation or median (interquartile range), and examined by Student t test or
ManneWhitney U test; categorical data expressed as percent distribution unless otherwise stated, and examined by Chi-square test.
b eGFR was derived from the four-variable Modification of Diet in Renal Disease Study equation.
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associated with less risk for ESRD [hazard ratio (HR), 0.847;
95% CI, 0.733e0.980; p Z 0.011] compared to the un-
treated group after adjusting the propensity score and
covariates. In addition, the concomitant uses of ACEI/ARB,
greater age, female sex, higher levels of baseline eGFR,
hemoglobin, and plasma albumin were associated with less
risk for ESRD (all p < 0.05; Table 4). Conversely, the pa-
tients with concomitant uses of antihypertensive drugs,
antidiabetic medication, diuretics, and erythropoietin
stimulating agents, higher blood levels of total cholesterol,
phosphate, as well as severe proteinuria were associated
with a higher risk for ESRD (all p < 0.05). The results of
prespecified subgroup analyses are shown in Fig. 1A. The
dipyridamole-treated group was associated with less risk
for ESRD in the nondiabetes mellitus subgroup (HR, 0.76;95% CI, 0.64e0.91) than the diabetes mellitus subgroup
(HR, 1.12; 95% CI, 0.86e1.45) with borderline significance
for interaction (p Z 0.063).Association between dipyridamole and all-cause
mortality
There were 101 patients (3.5 events/100 personeyears)
and 340 patients (5.8 events/100 personeyears) who died
in the dipyridamole-treated and untreated groups,
respectively. After adjusting covariates using the pro-
pensity score method, dipyridamole treatment was associ-
ated with reducing all-cause mortality by 23.5% (HR, 0.765;
95% CI, 0.606e0.971; p Z 0.001). Moreover, concomitant
uses of ACEI/ARB and antidiabetic drugs, female sex, higher
Table 2 Summary of medications prescribed in participants before and after inverse probability of treatment weighted
adjustment.
Characteristics Number of patients Percent distributiona
DIPY treated
(n Z 871)
DIPY untreated
(n Z 2203)
Before adjustment After adjustment
DIPY treated DIPY untreated DIPY treated DIPY untreated
RAAS blockades
ACEI 151 298 17.3 13.5* 15.7 13.7
ARB 388 1005 44.5 45.6 43.3 46.1
Other antihypertensive drugs
a-blockers 104 173 11.9 7.9* 9.1 7.7
b-blockers 185 475 21.2 21.6 21.7 21.3
Calcium channel blockers 338 785 38.8 35.6 35.8 36.5
Vasodilators 45 109 5.2 4.9 5.2 4.9
Antilipid drugs
Statins 223 560 25.6 25.4 25.9 25.3
Fibrates 21 78 2.4 3.5 2.4 3.5
Diuretics
Furosemide 163 391 18.7 17.7 17.6 18
Thiazides 33 55 3.8 2.5 3.3 2.5
Antidiabetic drugs
Insulin 64 209 7.3 9.5 8 7.6
OHD 173 566 19.9 25.7* 22 23
Others
Nitrates 48 196 5.5 8.9* 5.2 5.2
Aspirin 144 454 16.5 20.6* 18.3 18.3
Pentoxifylline 69 202 7.9 9.2 8.4 9.1
Phosphate binders 311 450 35.7 20.4* 14.2 13.7
ESA 286 592 32.8 26.9* 27.6 27.5
*p < 0.05 (DIPY treated vs. DIPY untreated).
ACEI Z angiotensin-converting enzyme inhibitor; ARB Z angiotensin II receptor blocker; DIPY Z dipyridamole; ESA Z erythropoietin
stimulating agent; OHD Z oral hypoglycemic drugs; RAAS Z renineangiotensinealdosterone system.
a Categorical data expressed as percent distribution unless otherwise stated, and examined by Chi-square test.
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were also associated with less all-cause mortality (all
p < 0.05). By contrast, use of diuretics, greater age,
comorbidities of CVD and diabetes, higher blood C-reactiveTable 3 Binary logistic regression analysis of estimated glomer
protein-to-creatinine (UPCR) ratio.
Medications eGFR
OR
Dipyridamole 0.755 (0.
ACEI/ARB 0.746 (0.
Other antihypertensive drugs 0.908 (0.
Antidiabetic drugs 1.122 (0.
Antilipid drugs 1.034 (0.
Diuretics 1.255 (0.
Aspirin 1.023 (0.
Phosphate binders 0.690 (0.
Nitrates 0.731 (0.
Pentoxifylline 0.912 (0.
*p < 0.05 indicates significant association with eGFR decline or progr
ACEI Z angiotensin-converting enzyme inhibitor; ARB Z angiotensin
a eGFR slope <5 mL/min/1.73 m2/y is defined as rapid renal prog
b Annual UPCR change >100 mg/g/y is defined as significant progreprotein level, and proteinuria were significantly associated
with increased risk of all-cause mortality (all p < 0.05). The
result of prespecified subgroup analyses showed insignifi-
cant interactions in all subgroups (Fig. 1B).ular filtration rate (eGFR) decline and progression of urinary
declinea UPCR progressionb
(95% CI) OR (95% CI)
595e0.958)* 0.655 (0.517e0.832)*
585e0.953)* 0.763 (0.605e0.963)*
639e1.291) 1.347 (0.996e1.822)
823e1.533) 0.863 (0.626e1.194)
798e1.343) 1.134 (0.864e1.489)
864e1.827) 2.099 (1.503e2.934)
728e1.440) 0.733 (0.523e1.030)
292e1.635) 2.468 (1.218e4.996)
428e1.248) 0.513 (0.315e0.834)
660e1.304) 0.952 (0.712e1.341)
ession of UPCR.
II receptor blocker; CI Z confidence interval; OR Z odds ratio.
ression.
ssion of proteinuria.
Table 4 Cox’s proportional hazard models of end-stage renal disease, all-cause mortality, and cardiovascular events.
Medications End-stage renal disease All-cause mortality Cardiovascular events
HR (95% CI) HR (95% CI) HR (95% CI)
Dipyridamole 0.847 (0.733e0.980)* 0.765 (0.606e0.971)* 1.018 (0.830e1.257)
ACEI/ARB 0.760 (0.651e0.889)* 0.619 (0.488e0.785)* 0.664 (0.534e0.826)*
Other antihypertensive drugs 1.286 (1.025e1.613)* 0.746 (0.543e1.029) 1.132 (0.835e1.536)
Antidiabetic drugs 1.353 (1.080e1.699)* 0.596 (0.443e0.803)* 1.201 (0.906e1.594)
Antilipid drugs 1.190 (1.000e1.419)* 0.812 (0.611e1.083) 1.057 (0.839e1.332)
Diuretics 1.393 (1.093e1.776)* 1.515 (1.077e2.133 1.817 (1.324e2.497)*
Aspirin 1.133 (0.912e1.412) 0.862 (0.620e1.198) 1.492 (1.134e1.966)*
Phosphate binders 1.249 (0.730e2.136) 0.770 (0.357e1.658) 1.480 (0.714e3.068)
Nitrates 0.864 (0.623e1.200) 0.733 (0.446e1.204) 1.208 (0.801e1.825)
Pentoxifylline 0.910 (0.643e1.287) 0.978 (0.858e1.115) 1.024 (0.787e1.226)
*p < 0.05 indicates significant association with end-stage renal disease, all-cause mortality, and cardiovascular events.
ACEIZ angiotensin-converting enzyme inhibitor; ARB Z angiotensin II receptor blocker; CI Z confidence interval; HRZ hazard ratio.
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cardiovascular events
There were 137 patients (4.7 events/100 personeyears) and
350 patients (5.9 events/100 personeyears) who had CV
events in the dipyridamole-treated and untreated groups,
respectively. As shown in Table 4, the dipyridamole-treated
group was not associated with lower risk for CV events. The
concomitant uses of ACEI/ARB, female sex, higher BMI, and
higher levels of plasma albumin were associated with lower
risk for CV events (all p < 0.05), whereas concomitant uses
of diuretics and aspirin, greater age, and previous CVD were
associated with higher risks for CV events (all p < 0.05).
Discussion
In our study, dipyridamole treatment was associated with
decreased risk for rapid renal progression, significant pro-
teinuria progression, development of ESRD, and all-cause
mortality in CKD stage 3e5 patients. These beneficial ef-
fects of dipyridamole were validated by using propensity
score methods for bias reduction [19,22]. This is the first
study to provide long-term positive effects of dipyridamole
on renal outcomes and patient survival in CKD patients.
There are several underlying mechanisms by which
dipyridamole may exert its renoprotective effects. First,
dipyridamole may inhibit platelet activation and aggrega-
tion by increasing adenosine level and inhibiting cAMP-
phosphodiesterase [23]. Moreover, it may stimulate vaso-
dilation via enhancing the nitric oxide pathway [24] and
also act as an antioxidant [25]. Additionally, dipyridamole
may exert renoprotective effects through inhibiting cellular
proliferation of human mesangial cells and renal fibroblasts
and extracellular matrix accumulation [26]. In vivo, dipyr-
idamole alone or along with ACEI has been proved to
attenuate renal progression and microalbuminuria via
increasing effective renal plasma flow in renal mass
reduction rats [27] and enhanced nitric oxide expression in
streptozotocin-induced diabetic rats [28].
In previous human studies, dipyridamole was found to
play an effective role in improving proteinuria in various
kidney diseases, which is consistent with our finding. Inpatients with IgA nephropathy, combination therapy of
dipyridamole, cyclophosphamide, and warfarin significantly
improved proteinuria [8,29]. A meta-analysis of antiplatelet
treatment for IgA nephropathy demonstrated the effica-
cious effect of dipyridamole in reducing the risk for pro-
teinuria by 41% [7]. In addition, dipyridamole alone or
combination therapy with aspirin or ACEI significantly
reduced proteinuria in diabetic nephropathy [6] and in
membranoproliferative glomerulonephritis [30].
However, the effect of dipyridamole on renal function
preservation of kidney diseases is controversial. Antiplate-
let therapy with dipyridamole treatment yielded a relative
risk reduction of renal progression in a meta-analysis for IgA
nephropathy [7]. By contrast, a study for IgA nephropathy
by Woo et al. [29,31] initially demonstrated stabilization of
renal function by combination therapy of dipyridamole with
cyclophosphamide and warfarin, but found no difference in
renal function between the treated and control groups in a
5-year post-trial assessment. Most of the other studies also
showed that combined therapy of dipyridamole with other
antiplatelet agents and immunosuppressants may improve
proteinuria but did not alter the renal function progression
in patients with IgA nephropathy [8], type 1 diabetes [32],
and membranoproliferative glomerulonephritis [9,30].
However, these studies were of small scale and did not
observe the hard renal outcomedESRD. Our study, which is
one of the largest studies of dipyridamole and includes
ESRD as an outcome, fills the gap in this field.
Another important finding from this study is that we
demonstrate a positive effect of dipyridamole on reducing
all-cause mortality in this advanced CKD cohort. Increased
all-cause and CV mortalities are the prominent worse out-
comes for patients with CKD [33]. It has been proposed that
bidirectional interactions between CKD and CVD lead to the
development of cardiorenal syndrome and accelerate the
disease process [34]. Both CKD and CVD share common risk
factors and aggravating factors, such as diabetes, hyper-
tension, dyslipidemia, and albuminuria. Treatment with
renineangiotensinealdosterone system blockade and anti-
platelet therapy would be the rational approach to modify
the disease progression and improve the outcomes of both
CVD and CKD. It is well established that antiplatelet agents
with aspirin or clopidogrel are effective in preventing
0.0 0.5 1.0 1.5 2.0
Male
Female
Age ≥ 65
Age < 65
DM
Non–DM
CVD
Non–CVD
Proteinuria (+)
Proteinuria (–)
RAAS blockade (+)
RAAS blockade (–)
CKD stage 3
CKD stage 4–5
Total 0.84 (0.73–0.97)
0.87 (0.75–1.00)
0.63 (0.29–1.35)
0.89 (0.72–1.11)
0.84 (0.68–1.03)
0.90 (0.50–1.64)
0.85 (0.74–0.99)
0.79 (0.67–0.93)
0.67 (0.42–1.07)
0.76 (0.64–0.91)
1.12 (0.86–1.45)
0.80 (0.67–0.97)
0.95 (0.75–1.20)
0.83 (0.67–1.02)
0.92 (0.75–1.13)
HR (95%CI)Subgroups
A
p of interaction
0.385
0.433
0.801
0.691
0.063
0.094
0.998
Adjusted hazard ratio (95% CI) for ESRD
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Figure 1. Effects of dipyridamole therapy in selected subgroups. The forest plots show the hazard ratio (HR) and 95% confidence
interval (CI) for: (A) end-stage renal disease (ESRD); and (B) all-cause mortality in selected subgroups of patients. CKD Z chronic
kidney disease; CVD Z cardiovascular disease; DM Z diabetes mellitus; RAAS Z renineangiotensinealdosterone system.
Dipyridamole and clinical outcomes in CKD 605stroke, myocardial infarction, and CV death [35]. Our study
has demonstrated a positive link of dipyridamole treatment
with reducing the risk of all-cause mortality. However,
neither dipyridamole nor aspirin exhibit the benefit in
reducing CV events in the current study. Previous reports
also showed the negative effect of clopidogrel in reducing
the CVD and death in patients with CKD [36]. There might be
a differential CV outcome in patients with CKD compared to
the general population despite preventive efforts.Additionally, CKD patients in Taiwan may have a higher
possibility of developing competitive risk for ESRD than
cardiovascular death as compared to western countries [37].
The current study provides several key findings of clini-
cally crucial significance. First, we prove the beneficial
effects of dipyridamole treatment on preventing ESRD in
patients with CKD stage 3e5. It has been well recognized
that proteinuria is a surrogate end point for progression of
kidney diseases [38]. It is reasonable to speculate that
606 C.-C. Hung et al.improving proteinuria progression might be one of the
mechanisms by which dipyridamole treatment reduces the
incidence of ESRD. Although these beneficial effects might
also be explained by the concurrent uses of ACEI/ARB or the
influence of other potential renoprotective drugs, dipyr-
idamole deserves more in-depth randomized clinical trials
to prove its independent renoprotective effect.
Second, the positive effect of dipyridamole in reducing
all-cause mortality is promising for patients with CKD when
targeting the improvement of patient survival, although
this beneficial effect could not be explained by altering the
CV events. A systemic review from 29 studies reported that
dipyridamole may be beneficial in decreasing recurrent
vascular events for patients with vascular diseases, but it
did not reduce the risk of vascular death [12]. More studies
are needed to explore the associated mechanisms of this
beneficial effect.
Third, some advanced CKD patients could not receive
ACEI/ARB because of hyperkalemia and renovascular dis-
ease. Dipyridamole could be a candidate drug in these pa-
tients. Finally, another major advantage of choosing
dipyridamole as an antiplatelet agent for CKD patients is for
its better tolerance compared to aspirin and lower cost
compared to clopidogrel.
However, there are several limitations in the current
study. First, this is an observational study, and hence the
causation of the observed relationships cannot be
confirmed. Second, baseline differences still existed be-
tween the dipyridamole-treated and untreated groups,
because propensity score technology could not consider all
the subtle differences between the groups. There could
still be selection bias. Third, this study lacks specific data
regarding other antiplatelet or antithrombotic agents, such
as cilostazol that may affect the renal progression [39,40].
Fourth, other medications such as uric acid lowering agents
and sodium bicarbonate could be beneficial for renal dis-
ease [41]. However, there are still controversies about
these medications and the percentage of their use was low
in our cohort. We therefore did not include them in our
analysis. Finally, our CKD patients received multiple reno-
protective agents other than dipyridamole, especially the
concurrent use of ACEI/ARB and other antihypertensive
drugs such as pentoxifylline [41]. Their effects alone or in
combination may not be eliminated by adjustment in the
model. These weaknesses might confound the interpreta-
tion of results.
In conclusion, our study demonstrates that dipyridamole
treatment is significantly associated with better renal
outcomes and patient survival in patients with CKD stages
3e5. These beneficial results may suggest that dipyr-
idamole treatment could be used as one of the interven-
tional approaches for CKD patients. It warrants further
investigations and randomized clinical trials to clarify the
mechanisms and confirm its independent positive effects.References
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